Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Once Weekly in Adolescents with Type 2 Diabetes
2015-000408-24Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide once weekly with Placebo (2 arms). Primary endpoint: Change in HbA1c from baseline to Week 24. Started Feb 2016; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-000408-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000408-24.